Accessibility Menu
MindWalk logo

MindWalk(NASDAQ) HYFT

Market Cap$63.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-69%
5 Year-81%
1 Year-33%
1 Month-9%
$1.46
+7.35%
+0.10Today
MindWalk last closing stock price
MetricPriceDate
Last closeUSD 1.442026-07-27
MindWalk stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.7%USD 1.432026-07-20
1 month-8.86%USD 1.582026-06-26
3 month+16.13%USD 1.242026-04-28
Year to date-20.88%USD 1.822025-12-31
1 year-33.33%USD 2.162025-07-25
3 year-45.04%USD 2.622023-07-28
5 year-80.51%USD 7.392021-07-28
Since inception-68.66%USD 4.342017-01-19

MindWalk Financials at a Glance

Market Cap

$63.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$15.45M

Net Income (TTM)

-CA$13.85M

EPS (TTM)

-$0.22

P/E Ratio

-6.24

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$1.46

Volume

445,607.934

Open

$1.41

Previous Close

$1.44

Daily Range

$1.37 - $1.50

52-Week Range

$0.99 - $3.25

Estimated Earnings Date

Aug 4, 2026

HYFT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MindWalk

ImmunoPrecise Antibodies Ltd. specializes in the discovery and development of therapeutic antibodies, offering a comprehensive suite of services to pharmaceutical and biotechnology markets. Its proprietary platform integrates state-of-the-art technologies for accelerated and precise antibody generation.

Products and Services

Antibody discovery services for therapeutic development

Custom monoclonal and polyclonal antibody production

Characterization and optimization of antibodies for improved efficacy

Integrated preclinical solutions to expedite drug development

What Makes ImmunoPrecise Antibodies Ltd. Special

ImmunoPrecise differentiates itself through its advanced platform that combines innovative technologies and methodologies, enhancing the precision and speed of antibody discovery. Its approach contrasts with traditional firms by using cutting-edge technology rather than outdated or singular techniques.

Five Things You Need to Know

The company's leadership comprises seasoned professionals with extensive biotech and pharmaceutical expertise.

ImmunoPrecise's strategic partnerships diversify revenue and advance its goal in therapeutic antibody development.

The company emphasizes a scalable business model, broadening service offerings and expanding its global reach.

Its proprietary platform underpins its competitive advantage in accelerating antibody generation.

ImmunoPrecise aims to capitalize on the growing demand for antibody therapeutics, fostering long-term growth.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

77

CEO

Jennifer L. Bath, PhD

Website

www.ipatherapeutics.com

Headquarters

Austin, TX 78701, US

HYFT Financials

Key Financial Metrics (TTM)

Gross Margin

58.79%

Operating Margin

-95.90%

Net Income Margin

-89.63%

Return on Equity

-90.61%

Return on Capital

-96.45%

Return on Assets

-64.91%

Earnings Yield

-16.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$63.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

46.71M

Volume

445.61K

Avg. Volume

365.99K

Financials (TTM)

Gross Profit

CA$9.09M

Operating Income

-CA$14.82M

EBITDA

-CA$13.95M

Operating Cash Flow

-CA$12.51M

Capital Expenditure

-CA$402.09K

Free Cash Flow

-CA$12.92M

Cash & ST Invst.

CA$11.33M

Total Debt

CA$3.52M

MindWalk Performance Analysis

MindWalk annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-04-30CAD 15,545,0960.7%
20242024-04-30CAD 18,157,23916.8%
20252025-04-30CAD 7,625,539-58.0%
20262026-04-30CAD 11,274,19747.8%
MindWalk sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-31-54.7%
Q22025-10-3130.5%
Q32026-01-31-0.8%
Q42026-04-30-0.3%
MindWalk annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-04-30CAD -0.8018.6%
20242024-04-30CAD -0.75-6.0%
20252025-04-30CAD -0.65-13.9%
20262026-04-30CAD -0.22-66.5%
MindWalk sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-31-10.4%
Q22025-10-310.1%
Q32026-01-31-18.9%
Q42026-04-301.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$4.08M

-41.6%

Gross Profit

CA$2.47M

-44.5%

Gross Margin

60.63%

N/A

Market Cap

$63.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$622.83K

N/A

Employees

102

N/A

Net Income

-CA$3.83M

-77.3%

EBITDA

-CA$4.06M

-310.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$11.33M

+6.2%

Total Debt

CA$3.52M

-73.7%

Accounts Receivable

CA$3.58M

-25.6%

Inventory

CA$491.17K

-76.6%

Long Term Debt

CA$3.06M

-73.5%

Short Term Debt

CA$456.23K

-75.3%

Return on Assets

-64.91%

N/A

Return on Invested Capital

-95.25%

N/A

Free Cash Flow

-CA$2.52M

-68.3%

Operating Cash Flow

-CA$2.51M

-119.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GUTSFractyl Health, Inc.
$0.80+3.62%
CLNNClene Inc.
$5.46+1.30%
CAMPCAMP4 Therapeutics Corporation
$3.42+8.23%
BYSIBeyondSpring Inc.
$1.17+4.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About HYFT

What is the current price of MindWalk?

MindWalk is trading at $1.44 per share.

What is the 52-week range for MindWalk?

Over the past 52 weeks, MindWalk has traded between $0.99 and $3.25.

How much debt does MindWalk have?

As of the most recent reporting period, MindWalk reported total debt of CA$2.59M.

How much cash does MindWalk have on hand?

MindWalk reported CA$8.34M in cash and cash equivalents in its most recent financial results.

What is MindWalk’s dividend yield?

MindWalk does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services